Figure 4. Anti-Nrp2B treatment in vitro results in reduced sprout formation and altered tip cell behavior. (A–C) Representative examples of LECs sprouting from coated beads in control (A), VEGF-C (B)–, or anti-Nrp2B (C)–treated cultures stained with anti–LYVE-1. (D) Sprout number is significantly reduced with anti-Nrp2B or VEGFR3 ECD treatment compared with VEGF-C treatment alone. (E) Sprout length is not reduced with anti-Nrp2B treatment but is reduced by VEGFR3 ECD treatment compared with VEGF-C treatment alone (n = 5 beads/well for 10 wells). (F–I) Quantification of sprout initiation events (F), sprout-stalling events (G), and sprout extension rates from live imaging experiments. Error bars indicate SEM. *, P < 0.01. Bar, 150 µm.
Figure 4.

Anti-Nrp2B treatment in vitro results in reduced sprout formation and altered tip cell behavior. (A–C) Representative examples of LECs sprouting from coated beads in control (A), VEGF-C (B)–, or anti-Nrp2B (C)–treated cultures stained with anti–LYVE-1. (D) Sprout number is significantly reduced with anti-Nrp2B or VEGFR3 ECD treatment compared with VEGF-C treatment alone. (E) Sprout length is not reduced with anti-Nrp2B treatment but is reduced by VEGFR3 ECD treatment compared with VEGF-C treatment alone (n = 5 beads/well for 10 wells). (F–I) Quantification of sprout initiation events (F), sprout-stalling events (G), and sprout extension rates from live imaging experiments. Error bars indicate SEM. *, P < 0.01. Bar, 150 µm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal